Rhythm Pharmaceuticals, Inc. (RYTM) is set to face a pivotal FDA decision tomorrow, March 20, 2026, on its sNDA to expand the label of Imcivree to include treatment of acquired hypothalamic obesity.
Imcivree (setmelanotide) is already FDA-approved for chronic weight management in adults and children aged two years and older with certain rare genetic forms of obesity, including Bardet-Biedl syndrome (BBS), POMC, PCSK1 or LEPR deficiency.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.